HBM4003

Clinical Trials Overview

1 trials found
About HBM4003

HBM4003 is an investigational medication currently being studied in clinical trials. It is being evaluated in combination with other investigational drugs like Toripalimab for patients with advanced neuroendocrine tumors (NET) and other solid tumors. The goal of these early-phase trials (Phase 1) is to determine the safety and tolerability of HBM4003, and to find the best dose for further studies. While the specific mechanism of action is being investigated, HBM4003 is being explored as a potential treatment option for various cancers. Currently, there is limited information available specifically about its use or effectiveness in colorectal cancer, as the provided trial focuses on NET and other solid tumors. More research is needed to understand its potential role in treating colorectal cancer.

Category Other Medications
Mechanism The specific way HBM4003 works (its mechanism of action) is still under investigation in clinical trials. It is being studied in combination with Toripalimab, another investigational drug. The trials aim to assess safety and determine appropriate dosages for future research.
1
Total Trials
0
Recruiting
1
Active
0
Completed
53
Total Enrollment
1
Countries
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
NCT05167071 Phase 1 Active 53 patients
Start: Dec 2021
End: Jun 2026
INTERVENTIONAL
Medications: HBM4003 Tislelizumab Toripalimab
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients with advanced NEN and...
China
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials